Cargando…

Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease

Drainage of interstitial fluid from the brain occurs via the intramural periarterial drainage (IPAD) pathways along the basement membranes of cerebral capillaries and arteries against the direction of blood flow into the brain. The cerebrovascular smooth muscle cells (SMCs) provide the motive force...

Descripción completa

Detalles Bibliográficos
Autores principales: Frost, Miles, Keable, Abby, Baseley, Dan, Sealy, Amber, Andreea Zbarcea, Diana, Gatherer, Maureen, Yuen, Ho Ming, Sharp, Matt MacGregor, Weller, Roy O., Attems, Johannes, Smith, Colin, Chiarot, Paul R., Carare, Roxana O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560129/
https://www.ncbi.nlm.nih.gov/pubmed/32971843
http://dx.doi.org/10.3390/ph13090261
_version_ 1783595018048503808
author Frost, Miles
Keable, Abby
Baseley, Dan
Sealy, Amber
Andreea Zbarcea, Diana
Gatherer, Maureen
Yuen, Ho Ming
Sharp, Matt MacGregor
Weller, Roy O.
Attems, Johannes
Smith, Colin
Chiarot, Paul R.
Carare, Roxana O.
author_facet Frost, Miles
Keable, Abby
Baseley, Dan
Sealy, Amber
Andreea Zbarcea, Diana
Gatherer, Maureen
Yuen, Ho Ming
Sharp, Matt MacGregor
Weller, Roy O.
Attems, Johannes
Smith, Colin
Chiarot, Paul R.
Carare, Roxana O.
author_sort Frost, Miles
collection PubMed
description Drainage of interstitial fluid from the brain occurs via the intramural periarterial drainage (IPAD) pathways along the basement membranes of cerebral capillaries and arteries against the direction of blood flow into the brain. The cerebrovascular smooth muscle cells (SMCs) provide the motive force for driving IPAD, and their decrease in function may explain the deposition of amyloid-beta as cerebral amyloid angiopathy (CAA), a key feature of Alzheimer’s disease. The α-adrenoceptor subtype α(1A) is abundant in the brain, but its distribution in the cerebral vessels is unclear. We analysed cultured human cerebrovascular SMCs and young, old and CAA human brains for (a) the presence of α(1A) receptor and (b) the distribution of the α(1A) receptor within the cerebral vessels. The α(1A) receptor was present on the wall of cerebrovascular SMCs. No significant changes were observed in the vascular expression of the α(1A)-adrenergic receptor in young, old and CAA cases. The pattern of vascular staining appeared less punctate and more diffuse with ageing and CAA. Our results show that the α(1A)-adrenergic receptor is preserved in cerebral vessels with ageing and in CAA and is expressed on cerebrovascular smooth muscle cells, suggesting that vascular adrenergic receptors may hold potential for therapeutic targeting of IPAD.
format Online
Article
Text
id pubmed-7560129
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75601292020-10-22 Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease Frost, Miles Keable, Abby Baseley, Dan Sealy, Amber Andreea Zbarcea, Diana Gatherer, Maureen Yuen, Ho Ming Sharp, Matt MacGregor Weller, Roy O. Attems, Johannes Smith, Colin Chiarot, Paul R. Carare, Roxana O. Pharmaceuticals (Basel) Article Drainage of interstitial fluid from the brain occurs via the intramural periarterial drainage (IPAD) pathways along the basement membranes of cerebral capillaries and arteries against the direction of blood flow into the brain. The cerebrovascular smooth muscle cells (SMCs) provide the motive force for driving IPAD, and their decrease in function may explain the deposition of amyloid-beta as cerebral amyloid angiopathy (CAA), a key feature of Alzheimer’s disease. The α-adrenoceptor subtype α(1A) is abundant in the brain, but its distribution in the cerebral vessels is unclear. We analysed cultured human cerebrovascular SMCs and young, old and CAA human brains for (a) the presence of α(1A) receptor and (b) the distribution of the α(1A) receptor within the cerebral vessels. The α(1A) receptor was present on the wall of cerebrovascular SMCs. No significant changes were observed in the vascular expression of the α(1A)-adrenergic receptor in young, old and CAA cases. The pattern of vascular staining appeared less punctate and more diffuse with ageing and CAA. Our results show that the α(1A)-adrenergic receptor is preserved in cerebral vessels with ageing and in CAA and is expressed on cerebrovascular smooth muscle cells, suggesting that vascular adrenergic receptors may hold potential for therapeutic targeting of IPAD. MDPI 2020-09-22 /pmc/articles/PMC7560129/ /pubmed/32971843 http://dx.doi.org/10.3390/ph13090261 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Frost, Miles
Keable, Abby
Baseley, Dan
Sealy, Amber
Andreea Zbarcea, Diana
Gatherer, Maureen
Yuen, Ho Ming
Sharp, Matt MacGregor
Weller, Roy O.
Attems, Johannes
Smith, Colin
Chiarot, Paul R.
Carare, Roxana O.
Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
title Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
title_full Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
title_fullStr Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
title_full_unstemmed Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
title_short Vascular α1A Adrenergic Receptors as a Potential Therapeutic Target for IPAD in Alzheimer’s Disease
title_sort vascular α1a adrenergic receptors as a potential therapeutic target for ipad in alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7560129/
https://www.ncbi.nlm.nih.gov/pubmed/32971843
http://dx.doi.org/10.3390/ph13090261
work_keys_str_mv AT frostmiles vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT keableabby vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT baseleydan vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT sealyamber vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT andreeazbarceadiana vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT gatherermaureen vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT yuenhoming vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT sharpmattmacgregor vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT wellerroyo vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT attemsjohannes vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT smithcolin vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT chiarotpaulr vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease
AT carareroxanao vasculara1aadrenergicreceptorsasapotentialtherapeutictargetforipadinalzheimersdisease